X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (940) 940
Book Chapter (5) 5
Conference Proceeding (3) 3
Book / eBook (2) 2
Publication (2) 2
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (388) 388
life sciences & biomedicine (383) 383
humans (343) 343
hematology (213) 213
male (213) 213
female (208) 208
middle aged (208) 208
aged (202) 202
oncology (178) 178
adult (171) 171
abridged index medicus (159) 159
aged, 80 and over (133) 133
leukemia, lymphocytic, chronic, b-cell - drug therapy (124) 124
treatment outcome (109) 109
chronic lymphocytic leukemia (83) 83
hemic and lymphatic diseases (83) 83
leukemia (80) 80
prognosis (78) 78
antineoplastic combined chemotherapy protocols - therapeutic use (73) 73
leukemia, lymphocytic, chronic, b-cell - pathology (71) 71
leukemia, lymphocytic, chronic, b-cell - genetics (67) 67
antineoplastic agents - therapeutic use (55) 55
rituximab (52) 52
care and treatment (51) 51
disease-free survival (51) 51
adolescent (47) 47
cancer (47) 47
hematology, oncology and palliative medicine (45) 45
leukemia, lymphocytic, chronic, b-cell - mortality (43) 43
vidarabine - analogs & derivatives (43) 43
leukemia, lymphocytic, chronic, b-cell - therapy (41) 41
patients (41) 41
chronic lymphatic leukemia (38) 38
retrospective studies (38) 38
follow-up studies (37) 37
research (37) 37
immune system diseases (35) 35
mutation (35) 35
cll (34) 34
lymphoid neoplasia (34) 34
dose-response relationship, drug (33) 33
survival rate (33) 33
animals (31) 31
antineoplastic combined chemotherapy protocols - adverse effects (31) 31
drug administration schedule (31) 31
risk factors (31) 31
analysis (30) 30
chemotherapy (30) 30
leukemia, lymphocytic, chronic, b-cell - metabolism (30) 30
recurrence (30) 30
remission induction (29) 29
survival analysis (29) 29
young adult (29) 29
antibodies, monoclonal - therapeutic use (28) 28
cyclophosphamide - administration & dosage (28) 28
disease progression (28) 28
drug therapy (28) 28
patient outcomes (28) 28
pyrimidines - therapeutic use (28) 28
vidarabine - administration & dosage (28) 28
kaplan-meier estimate (27) 27
leukemia, lymphocytic, chronic, b-cell - immunology (27) 27
antibodies, monoclonal - administration & dosage (26) 26
clinical trials and observations (26) 26
flow cytometry (26) 26
leukemia, lymphocytic, chronic, b-cell - diagnosis (26) 26
lymphatic leukemia (26) 26
antineoplastic agents - administration & dosage (24) 24
survival (24) 24
antibodies, monoclonal, murine-derived (23) 23
antineoplastic agents - adverse effects (23) 23
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (23) 23
tyrosine (23) 23
apoptosis - drug effects (22) 22
drug resistance, neoplasm (22) 22
immunotherapy (22) 22
protein-tyrosine kinases - antagonists & inhibitors (22) 22
medical research (21) 21
neoplasm staging (21) 21
pyrimidines - administration & dosage (21) 21
alemtuzumab (20) 20
antineoplastic combined chemotherapy protocols - administration & dosage (20) 20
clinical trials (20) 20
lymphomas (20) 20
tumor cells, cultured (20) 20
dosage and administration (19) 19
leukemia, lymphocytic, chronic, b-cell - blood (19) 19
multivariate analysis (19) 19
protein-tyrosine kinase (19) 19
time factors (19) 19
antineoplastic agents - pharmacology (18) 18
ibrutinib (18) 18
lymphocytes b (18) 18
mice (18) 18
antibodies, monoclonal, humanized (17) 17
apoptosis (17) 17
neoplasms (17) 17
antibodies, monoclonal - adverse effects (16) 16
chromosome deletion (16) 16
proportional hazards models (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, Cambridge studies in romanticism, ISBN 9780521768146, Volume 93, vii, 305
How and why childhood became so important to such a wide range of Romantic writers has long been one of the central questions of literary historical studies.... 
History and criticism | Children in literature | Romanticism | English literature | Great Britain | 19th century | Eighteenth Century | Nineteenth Century | British Literature | Childhood | English Literature | General
Book
The lancet oncology, ISSN 1470-2045, 06/2016, Volume 17, Issue 6, pp. 768 - 778
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 09/2014, Volume 15, Issue 10, pp. 1090 - 1099
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 07/2013, Volume 369, Issue 1, pp. 32 - 42
Journal Article